\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update.\n<\/p>\n
\n\u201cLooking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response,\u201d stated Purnanand Sarma, Ph.D., President and CEO of Immunome. \u201cWe look forward to continuing to execute on our momentum throughout the upcoming year as we advance our pipeline, including an IND submission for our lead oncology program, IMM-ONC-01 (anti-IL-38 antibody), and working closely with AbbVie on our collaboration to ultimately make a difference in cancer patients\u2019 lives.\u201d\n<\/p>\n
Highlights<\/b><\/p>\n Financial Highlights<\/b><\/p>\n About Immunome<\/b><\/p>\n \nImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company\u2019s focus is on discovering and developing therapeutics in oncology internally and in collaboration with our partners. For more information, please visit www.immunome.com<\/a> or follow us on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n About Immunome\u2019s Discovery Engine<\/b><\/p>\n \nImmunome\u2019s proprietary Discovery Engine identifies novel therapeutic antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome\u2019s Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data we generate differentiates our approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility.\n<\/p>\n IMMUNOME, INC.<\/b><\/p>\n<\/td>\n<\/tr>\n \nCondensed Balance Sheets\n<\/p>\n<\/td>\n<\/tr>\n \n(In thousands, except share data)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n December 31,<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2021<\/b><\/p>\n<\/td>\n<\/tr>\n \n20,323\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n49,229\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n2,326\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n7,409\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n22,649\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n56,638\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n681\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n855\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n284\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u2014\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n100\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n100\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n332\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n332\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n24,046\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n57,925\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n2,400\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n3,077\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n4,931\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n6,651\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n7,331\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n9,728\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n62\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n12\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n7,393\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n9,740\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n\u2014\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u2014\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n1\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n1\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n132,653\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n127,289\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n(116,001\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n \n(79,105\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n<\/tr>\n \n16,653\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n48,185\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n24,046\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n57,925\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n IMMUNOME, INC.<\/b><\/p>\n<\/td>\n<\/tr>\n \nCondensed Statements of Operations\n<\/p>\n<\/td>\n<\/tr>\n \n(In thousands, except share and per share data)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n Year ended December 31,<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2021<\/b><\/p>\n<\/td>\n<\/tr>\n \n23,272\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n14,110\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n13,629\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n11,094\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n36,901\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n25,204\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n(36,901\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n \n(25,204\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2014\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n503\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n5\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n(10\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n<\/tr>\n \n5\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n493\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n(36,896\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n \n(24,711\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n<\/tr>\n \n(622\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n \n\u2014\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n(37,518\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n \n(24,711\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n<\/tr>\n \n(3.09\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n \n(2.14\n<\/p>\n<\/td>\n \n)\n<\/p>\n<\/td>\n<\/tr>\n \n12,126,573\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n11,538,668\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230316005309\/en\/<\/a><\/span><\/p>\n Immunome Contact Investor Contact\n
\n
\n
\n
\n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Assets<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Current assets:<\/td>\n \n \n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Prepaid expenses and other current assets<\/td>\n \n \n \n \n \n \n \n \n \n Total current assets<\/td>\n \n \n \n \n \n \n \n \n \n Property and equipment, net<\/td>\n \n \n \n \n \n \n \n \n \n Operating right-of-use asset, net<\/td>\n \n \n \n \n \n \n \n \n \n Restricted cash<\/td>\n \n \n \n \n \n \n \n \n \n Deferred offering costs<\/td>\n \n \n \n \n \n \n \n \n \n Total assets<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Liabilities and stockholders\u2019 equity<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Current liabilities:<\/td>\n \n \n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Accrued expenses and other current liabilities<\/td>\n \n \n \n \n \n \n \n \n \n Total current liabilities<\/td>\n \n \n \n \n \n \n \n \n \n Other long-term liabilities<\/td>\n \n \n \n \n \n \n \n \n \n Total liabilities<\/td>\n \n \n \n \n \n \n \n \n \n Commitments and contingencies (Note 8)<\/td>\n \n \n \n \n \n <\/tr>\n \n Stockholders\u2019 equity:<\/td>\n \n \n \n \n \n <\/tr>\n \n Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2022 and December 31, 2021<\/td>\n \n \n \n \n \n \n \n \n \n Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,128,843 shares issued and outstanding at December 31, 2022 and 12,110,373 shares issued and outstanding at December 31, 2021<\/td>\n \n \n \n \n \n \n \n \n \n Additional paid-in capital<\/td>\n \n \n \n \n \n \n \n \n \n Accumulated deficit<\/td>\n \n \n \n \n \n \n \n \n \n Total stockholders\u2019 equity<\/td>\n \n \n \n \n \n \n \n \n \n Total liabilities and stockholders\u2019 equity<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Operating expenses:<\/td>\n \n \n \n \n \n <\/tr>\n \n Research and development<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n General and administrative<\/td>\n \n \n \n \n \n \n \n \n \n Total operating expenses<\/td>\n \n \n \n \n \n \n \n \n \n Loss from operations<\/td>\n \n \n \n \n \n \n \n \n \n Other income (expense):<\/td>\n \n \n \n \n \n <\/tr>\n \n Other income<\/td>\n \n \n \n \n \n \n \n \n \n Interest income (expense), net<\/td>\n \n \n \n \n \n \n \n \n \n Total other income<\/td>\n \n \n \n \n \n \n \n \n \n Net loss<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Deemed dividend arising from warrant modification<\/td>\n \n \n \n \n \n \n \n \n \n Net loss attributable to common stockholders<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Per share information:<\/td>\n \n \n \n \n \n <\/tr>\n \n Net loss per common share, basic and diluted<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n Weighted-average common shares outstanding, basic and diluted<\/td>\n \n \n \n \n \n \n \n \n <\/p>\n
\n<\/b>
Corleen Roche
\n
Chief Financial Officer
\n
Immunome, Inc.
\n
investors@immunome.com
\n<\/a><\/p>\n
\n<\/b>
Laurence Watts
\n
Managing Director
\n
Gilmartin, LLC
\n
laurence@gilmartinir.com
\n<\/a><\/p>\n